Cullinan Therapeutics, Inc. (CGEM)
11.31
+0.51
(+4.72%)
USD |
NASDAQ |
Nov 06, 16:00
11.29
-0.02
(-0.18%)
After-Hours: 20:00
Cullinan Therapeutics Research and Development Expense (Annual) : 187.40M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 187.40M |
| December 31, 2024 | 142.90M |
| December 31, 2023 | 148.16M |
| December 31, 2022 | 91.95M |
| Date | Value |
|---|---|
| December 31, 2021 | 57.75M |
| December 31, 2020 | 43.21M |
| December 31, 2019 | 16.79M |
| December 31, 2018 | 9.584M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Climb Bio, Inc. | 46.62M |
| MapLight Therapeutics, Inc. | 138.35M |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |
| Oncolytics Biotech, Inc. | 13.31M |
| Sangamo Therapeutics, Inc. | 112.67M |